PSI researchers identify potential active agent against several unicellular parasites – including the pathogens that cause malaria and toxoplasmosis.
The University Hospital of Zurich uses proteins made at PSI for Europe’s first large-scale serology study on coronavirus prevalence in Switzerland.
Crystal structure analysis, computer models, cell cultures – to pursue research on Sars-CoV-2, PSI is exploring many avenues. An overview.
A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases.
Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.
Imaging and sequencing techniques combined with machine learning offer researchers countless opportunities to look inside cells with greater precision than ever before. G.V. Shivashankar, lab head at PSI, describes how such information can be used to find answers to pressing questions.
At PSI, researchers decipher the structure of the proteins in bacteria and viruses. This knowledge can aid, for example, in the development of drugs against infectious diseases. But before the investigation can begin, an extremely tricky problem has to be solved: the crystallisation of the molecules.
Researchers have coaxed a secret out of the vital protein cytochrome c that it kept well-hidden up to now. Measurements at the X-ray free-electron laser SwissFEL reveal structural changes that science had previously ruled out for this kind of biomolecule.
PSI researchers have found a more effective treatment for a form of thyroid cancer – and with fewer side effects – by increasing the uptake of the cancer drug in tumour cells. The results have been published in the medical journal Theranostics.
The world of microbes and viruses is extremely old and exceedingly diverse. With the large research facilities at PSI, researchers are peering deep inside this alien cosmos and investigating, above all, the proteins of these exotic beings.
For the first time, researchers at the Centre for Proton Therapy at PSI have tested ultrafast, high-dose irradiation with protons. The new, experimental FLASH technique could revolutionise radiation therapy for cancer.
In the service of health, scientists at the Paul Scherrer Institute PSI work with radionuclides and develop agents to treat cancer and to detect tumours. Their research provides support to hospitals and is of great interest to Swiss industry.
At the treatment stations of the Centre for Proton Therapy at PSI, tumours can be precisely irradiated from any direction. An interactive graphic explains how the protons get from the source to the body in order to trigger the elimination of tumour tissue.
Proton therapy is time-consuming and more costly than conventional radiation therapy, but its accuracy in targeting tumours is unsurpassed. An interview with Damien Weber, head of the Centre for Proton Therapy at PSI.
At PSI, cancer patients receive a therapy that is unique in Switzerland. Bombardment with protons wipes out cancer cells – and does so more precisely than with any other form of irradiation.
Researchers at the Paul Scherrer Institute PSI, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the development of an active substance against the metastasis of certain cancers. Using the Swiss Light Source SLS, they deciphered the structure of a receptor that plays a crucial role in the migration of cancer cells.
Researchers at the Paul Scherrer Institute PSI have an important part of the regulatory cycle that is involved in the formation and degradation of the cytoskeleton. Among other things, they have watched molecular scissors at work.
Researchers at the Paul Scherrer Institute PSI have elucidated an important part of a siganalling pathway that transmits information through the cell membrane into the interior of a cell. This exists in all mammals and plays an important role, among other things, in the regulation of the heartbeat. The new findings could lead to new therapies.
At PSI, Beate Timmermann built up a programme providing proton therapy for children with cancer at the same time she was raising her own son. Today she is head of the Clinic for Particle Therapy at the West German Proton Therapy Centre in Essen (WPE) and is considered one of the most accomplished experts in this field.
A radioactive agent, developed at the Paul Scherrer Institute PSI to fight an especially malignant form of thyroid cancer, has the potential to become a blockbuster drug. Due to its structure, it might also be able to dock onto cells of other tumours and destroy them with its radiation. The Lausanne-based biopharmaceutical company Debiopharm wants to further develop the PSI agent to the point where it is approved as a drug. Debiopharm and PSI have now created the contractual basis for this.